9-ING-41 (Synonyms: Elraglusib) |
| Katalog-Nr.GC39152 |
9-ING-41 ist ein Maleimid-basierter ATP-kompetitiver und selektiver Glykogen-Synthase-Kinase-3β (GSK-3β)-Inhibitor mit einem IC50 von 0,71 μM. 9-ING-41 fÜhrt signifikant zu Zellzyklusstillstand, Autophagie und Apoptose in Krebszellen. 9-ING-41 hat AntikrebsaktivitÄt und hat das Potenzial, die Antitumorwirkung von Chemotherapeutika zu verstÄrken.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1034895-42-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
9-ING-41 is a potent glycogen synthase kinase-3 (GSK-3) inhibitor[1]. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK-3β. 9-ING-41 has anticancer activity[2].
[1]. Ugolkov AV, et al. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. [2]. Wu X, et al. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *